SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

ICAD

21.18

+1.92%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

ICAD

21.18

+1.92%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

ICAD

21.18

+1.92%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

ICAD

21.18

+1.92%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

ICAD

21.18

+1.92%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

53.1 -0.28

Visão Geral

Variação de preço das ações

24h

Atual

Mín

52.95

Máximo

53.75

Indicadores-chave

By Trading Economics

Rendimento

-1.2M

22M

Vendas

4.8M

160M

P/E

Médio do Setor

22.008

40.048

EPS

0.354

Rendimento de Dividendos

1.64

Margem de lucro

13.547

Funcionários

2,188

EBITDA

-107M

31M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+69.33% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.64%

2.45%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

94M

2.9B

Abertura anterior

53.38

Fecho anterior

53.1

Sentimento de Notícias

By Acuity

50%

50%

175 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2025, 21:42 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 de ago. de 2025, 21:21 UTC

Ganhos
Grandes Movimentos do Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 de ago. de 2025, 20:45 UTC

Ganhos

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 de ago. de 2025, 19:15 UTC

Grandes Movimentos do Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de ago. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

4 de ago. de 2025, 23:28 UTC

Conversa de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 de ago. de 2025, 21:30 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 21:21 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 de ago. de 2025, 21:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 de ago. de 2025, 20:25 UTC

Conversa de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss $938M >RIG

4 de ago. de 2025, 20:25 UTC

Ganhos

Transocean 2Q Loss/Shr $1.06 >RIG

4 de ago. de 2025, 20:18 UTC

Ganhos

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 de ago. de 2025, 20:15 UTC

Ganhos

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 de ago. de 2025, 20:14 UTC

Ganhos

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 de ago. de 2025, 20:13 UTC

Ganhos

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 de ago. de 2025, 20:09 UTC

Ganhos

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 de ago. de 2025, 20:06 UTC

Ganhos

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 de ago. de 2025, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 de ago. de 2025, 19:41 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 de ago. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 de ago. de 2025, 19:07 UTC

Conversa de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 de ago. de 2025, 18:27 UTC

Conversa de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

69.33% parte superior

Previsão para 12 meses

Média 90 EUR  69.33%

Máximo 90 EUR

Mínimo 90 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

175 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.